.15e4dc1dd95d816d.png)
TechInvention's state-of-the-art R&D facility, the High-impact One Health Research & Innovation ZONe (HORIZON), is designed to accelerate vaccine innovation by supporting end-to-end research from proof-of-concept development through preclinical advancement for priority infectious diseases and antimicrobial resistance (AMR)-associated pathogens.
Target identification, antigen discovery, AI/ML-enabled vaccine design, and platform selection.
Process and formulation development, analytical assay development, characterization, and proof-of-concept studies.
Preclinical efficacy, safety and toxicology studies, with regulatory documentation and compliance.
Process scale-up, technology transfer, GMP manufacturing readiness, and commercial translation.
Together, our partnerships are focused on high-priority diseases of major public health significance, including Salmonella, Shigella, tuberculosis, malaria, and meningitis strengthening the pathway from scientific discovery to translational development and future vaccine impact.
Connect with us to explore collaborations, licensing partnerships, and capacity-building opportunities for vaccines and biotherapeutics globally.